FDA says J&J halted Doribax trial due to safety issues

WASHINGTON (Reuters) – Johnson & Johnson shut down a clinical trial of its antibiotic Doribax for a type of pneumonia after patients taking the drug had higher rates of death and a lower cure rate than those who got an alternative medicine, …
See all stories on this topic »